Semaglutide Trial to Reduce Alcohol Use and Heart Risk in HIV Patients

Individuals living with HIV face an elevated risk of cardiovascular disease (CVD) and often struggle with alcohol use disorder and tobacco smoking, which further exacerbate health complications. Current interventions for these co-occurring issues in the HIV population are often insufficient. This upcoming randomized controlled trial aims to address the critical gap in understanding whether semaglutide can effectively reduce alcohol consumption, smoking, and mitigate CVD risk among adults living with HIV.

As this is a "NOT_YET_RECRUITING" study, there are no findings to report yet. However, the trial is designed to determine if semaglutide can significantly impact several key outcomes. Researchers hypothesize that semaglutide will lead to a measurable decrease in the average number of alcoholic beverages consumed per week and the average number of cigarettes smoked per day. The study will also assess if semaglutide can reduce the risk factors associated with cardiovascular disease in this specific patient population. The primary objective is to quantify any reduction in the average number of alcoholic beverages participants drink per week when treated with semaglutide compared to placebo. Secondary objectives include evaluating changes in smoking frequency and various CVD risk markers, aiming to show a beneficial effect of semaglutide over the control group.